仁和藥業(000650.SZ):生產銷售的小兒氨酚烷胺顆粒也可用於兒童流行性感冒的預防和治療
格隆匯10月16日丨仁和藥業(000650.SZ)在投資者互動平台表示,肺炎支原體是一種介於細菌和病毒之間的微生物,容易在人羣密集、通風不良的環境中通過飛沫或直接接觸傳播。公司生產銷售的小兒氨酚烷胺顆粒(優卡丹)適用於緩解兒童普通感冒及流行性感冒引起的發熱、頭痛、四肢痠痛、打噴嚏、流鼻涕、鼻塞、咽痛等症狀,也可用於兒童流行性感冒的預防和治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.